Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma

Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma - Efficacy and safety of lenalidomide and dexamethasone as consolidation therapy and lenalidomide as maintenance therapy after autologous stem cell transplantation for newly diagnosed multiple myeloma (GHSG MM-02)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019918

Enrollment

Registered

2015-11-24

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple myeloma

Interventions

blank

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: blank

Exclusion criteria

Exclusion criteria: blank

Design outcomes

Primary

Measure	Time frame
Rate of complete response (CR) plus very good partial response (VGPR) after lenalidomide and dexamethasone as consolidation therapy	—

Secondary

Measure	Time frame
(1) Rate of complete response plus very good partial response after lenalidomide as maintenance therapy (2) Safety: Hematological toxicity of grade 4, non-hematological toxicity of grade 3 to 4, and the secondary malignancy (3) Overall survival (4) Progression-free survival (the rate of patients who are not recognized as having progression or recurrence)	—

Countries

Japan

Contacts

Public ContactJunichi Kitagawa

Gifu University Hospital Department of hematology

jkitagawa1128@gmail.com058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026